4,192.00
-3.45%
Close of 9 Nov 2026, in ILA
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Bio View
Its shares trade on Tel Aviv under the ticker BIOV.TA. It has been listed since 7 March 2006. In the fiscal year to 31 December 2025, it reported revenue of ILS 19.9m and a net loss of ILS 15.3m. At that date it held total assets of ILS 19.9m and shareholders' equity of ILS 9.4m.
BioView Ltd. engages in the research, development, marketing, and sales of imaging systems computerized to identify abnormal cells. The firm manufactures and assembles, markets and services an automated cell diagnostic system for use in cytology, cytogenetic, hematology and pathology laboratories. The workstation is called Duet, which provides automated detection, classification, analysis, and counting of cells for diagnosis and study. Additionally, Duet provides a method to analyze both the morphology and the genetic content of the same cell. The firm has applications in Cancer diagnosis and follow-up of minimal-residual disease (MRD); in pre-natal and post-natal Cytogenetic analyses in the analysis of sperm cells and rare-cell detection (RCD). In 2005, the Company introduced two new scanning workstations: the ALLEGRO, for automated scanning of Fluorescence in-situ Hybridization (FISH) probes without Brightfield scanning, and the ACCORD, for the semi-automated imaging of FISH for breast cancer (Her-2/Neu) and for FISH on tissue.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 7 Mar 2006
- Website
- bioview.com ↗
Leadership
Pay as last reported
- Emmanuel GillChairman of the Board, since 2000
- Dr. Alan SchwebelChief Executive Officer, DirectorILS 771,000
- Ms. Yulia Oroniuk KaponChief Financial Officer
- Mr. David KutasPresident of Bio View (USA) IncILS 916,000
- Mr. Yuval HarariExecutive Vice President, since 2000ILS 634,000
- Ms. Inbal Shmula HillelVice President - Operations
- Elad KfirVice President of Marketing
- Mr. Warren EsanuDirector
- Mr. Yacha SuttonDirector
- Mr. Eliyahu Ayalon-LancianoExternal Director
- Dr. Eliane MarkowitzExternal Director
- Jackie Rosenblum-GorenExternal Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Bio View Ltd's Duet workstation identifies abnormal cells in cytology and pathology labs.
- Duet provides automated detection and analysis of cell morphology and genetic content.
- ALLEGRO and ACCORD scanning workstations enhance FISH probe analysis for cancer diagnosis.
Weaknesses
- Bio View Ltd's business is limited to Health Care sector with no diversification.
- The company's products are specific to laboratory diagnostics with narrow market applications.
- Duet and ALLEGRO workstations require specialized training for effective use.
Opportunities
- Expanding into pre-natal and post-natal cytogenetic analyses offers new market segments.
- Growing demand for minimal-residual disease (MRD) follow-up in cancer treatment increases opportunities.
- The ACCORD workstation for breast cancer analysis can target expanding oncology markets.
Threats
- Competition from established medical imaging companies poses a threat to market share.
- Regulatory changes in Health Care could impact product approvals and sales.
- Economic downturns may reduce laboratory budget allocations for new equipment.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.